Biotech Startups

Kintsugi Therapeutics is a preclinical-stage biopharmaceutical company developing first-in-class endoplasmic reticulum stress inhibitors for treating non-alcoholic steatohepatitis and other liver conditions.

2 investors

KisoJi Biotechnology discovers and develops differentiated antibody therapeutics targeting difficult targets in oncology and other diseases. Its platform combines proprietary multi-species single domain antibody transgenic mice, AI-enabled antibody fingerprinting, and multi-specific antibody engineering for therapeutic, diagnostic, and vaccine development.

2 investors

2 investors

Kite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.

2 investors

Kivo is a document management system for life sciences organizations that ensures GxP compliance through 21 CFR Part 11 e-signatures, access controls, and audit trails. The platform integrates DocuSign and Microsoft Office to support collaborative authoring, approval workflows, training assignments, and real-time compliance reporting.

2 investors

FODZYME develops an enzyme powder supplement that breaks down FODMAPs in food, particularly fructans found in garlic, onions, and wheat, for people with digestive sensitivities. The product targets individuals who need to manage FODMAP intolerance to improve their diet flexibility and quality of life.

2 investors

Kiwi Biosciences develops patent-pending enzymes and incorporates them into consumer products such as dietary supplements and foods. Its FODZYME product is an enzyme supplement that breaks down FODMAPs — fructan, galacto-oligosaccharides, and lactose — to reduce digestive symptoms for people with sensitive guts.

2 investors

KIYATEC develops 3D Predict, a tumor-specific testing platform that uses patient-derived tumor cells to predict how individual cancers respond to therapies. It serves oncologists and cancer patients in the precision oncology and diagnostics space.

2 investors

KLISBio develops a silk fibroin-based biointegrative platform for nerve repair and other medical applications. The company serves medtech markets focused on biocompatible medical devices and biomaterials.

2 investors

Knopp Biosciences is a privately held company that manages a portfolio of future milestone payments and product royalties from drug pipelines it sold or spun off in 2022. Its Kv7 small-molecule platform for epilepsy and hyperexcitability disorders was acquired by Biohaven Pharmaceuticals, and its dexpramipexole platform was spun off to Areteia Therapeutics.

2 investors

KOA Biotech develops early pathogen detection technology for aquaculture to reduce fish mortality and antibiotic use. The company serves aquaculturists seeking to improve productivity and sustainability in fish farming.

2 investors

Kometa Bio develops dental surgical devices, specifically the Smart Dentin Grinder, which processes autologous dentin for bone augmentation procedures in dental practice.

2 investors

KOMO Biosciences develops genome engineering technology based on hyperactive large serine integrases to transform cell-based manufacturing of biologics and advanced therapies. The company was founded around record-breaking integrase technology for improving gene editing vectors.

2 investors

Koru Diagnostics develops StaphGold, a milk screening ELISA test that detects subclinical Staphylococcus aureus mastitis in dairy herds using existing milk recording samples. It serves dairy farmers and vets to inform herd treatment decisions, improve milk quality and yield, and reduce mastitis spread.

2 investors

Kovina develops first-in-class small molecule antiviral drugs to treat HPV-induced cancers and premalignant infections such as cervical and anal dysplasia. The company aims to offer non-surgical treatment options for patients living with HPV.

2 investors

Serkanto AI is a platform that uses machine learning and deep learning to identify and validate bioactive RNAs in medicinal plants, fungi, and fresh foods for natural ingredient development. The platform serves food, supplement, and cosmetics companies by predicting bioactive RNA candidates, validating them through laboratory assays, and producing stabilized bioactive ingredients.

2 investors

Krystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions. The company operates across the US, Europe, and Japan.

2 investors

Kuros Biosciences is a Swiss biotech company developing biologic technologies for bone healing and bone grafts, primarily for spine, extremities, and pelvis surgical applications. Originally a spin-off of the Swiss Federal Institute of Technology in Zurich, it is publicly listed on the SIX Swiss Stock Exchange and operates in Switzerland, the Netherlands, and the USA.

2 investors

KyDo Therapeutics is a preclinical-stage biotechnology company developing novel covalent-allosteric small molecule inhibitors intended to become best-in-class oncology drugs. Its lead programs target hard-to-treat cancers such as glioblastoma, and the company is based in Dortmund, Germany.

2 investors

Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases. Its lead program is in a Phase 2 trial for cognitive impairment associated with schizophrenia (CIAS), with expansion planned into Alzheimer's disease.

2 investors

Kypha develops clinical diagnostic tests for immune system biomarkers, particularly complement activity markers, and provides solutions for real-time immune insights across therapeutic areas. The company serves biopharma firms, clinical laboratories, and medical institutions through a network of clinical collaborators and research partners.

2 investors

Kyron.bio is a biotechnology company focused on developing therapeutic drugs, with an in-house R&D and laboratory operation.

2 investors

L-Nutra develops fasting-mimicking technology and nutrition-based products designed to slow biological aging and treat age-related diseases. The company focuses on translating longevity research into consumer health interventions.

2 investors

LabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.

2 investors